LinkML turns preclinical metadata into executable schemas

A schema is more than a checklist

A checklist tells a scientist what should be recorded. A schema tells software what must be present, what type each field has, what controlled values are allowed, and how one object relates to another. For NAMs and other preclinical assays, that difference matters because missing metadata often becomes visible only when someone tries to reuse the data.

LinkML is designed for this middle ground between human-readable modelling and executable software artefacts. A schema can be written in YAML, then compiled into validation rules, JSON Schema, JSON-LD contexts, RDF mappings, OWL, SHACL or ShEx shapes, GraphQL, Python classes, and documentation.

Why this fits preclinical data

Preclinical datasets mix biological entities, interventions, devices, timelines, endpoints, software, and evidence claims. A pure table struggles with that structure. LinkML lets a team model objects such as animal, cell line, donor, organoid, test article, exposure, endpoint, assay run, analysis step, and validation result as linked classes with explicit relationships.

The practical benefit is consistency. The same schema can drive a web form, spreadsheet template, API contract, validation service, and warehouse mapping. When the schema changes, the downstream artefacts can be regenerated rather than manually reconciled.

NAMO is the relevant example

NAMO demonstrates this pattern for New Approach Methodologies. It uses LinkML to model organoids, organ-on-chip systems, in silico models, validation evidence, and concordance across biological dimensions. That is useful because NAM data does not fit one flat structure. A QSAR model, a Liver-Chip assay, and a brain organoid protocol need shared concepts but different required fields.

A sponsor does not need to adopt NAMO unchanged. The more practical route is to use NAMO as a semantic anchor, then define local profiles for specific contexts of use. Those profiles can require the fields that matter for a hepatotoxicity MPS assay, a PBPK model, or a high-content imaging endpoint.

Validation should be built into the workflow

The key implementation decision is where validation happens. If validation happens after publication or during submission assembly, the schema becomes a repair tool. If it happens during protocol design, data capture, and analysis freeze, the schema becomes quality control.

A simple first version can be modest: a LinkML schema, JSON examples, a validation command, and a small report listing missing fields and invalid terms. That is enough to make metadata quality visible before data enters a warehouse or evidence package.